Joint Conference of European Human Pharmacological Societies CLUB PHASE I (France), AGAH (Germany), BAPU (Belgium), AHPPI (UK)

Posted:
28
February 2013

Please join us at theJoint Conference of European Human Pharmacological Societies CLUB PHASE I (France), AGAH (Germany), BAPU (Belgium), AHPPI (UK)11 & 12 April 2013Nice Sophia Antipolis, FranceThe meeting will focus on Early Clinical Utility Assessment of new medicines and how early development should be conducted to optimize the challenging process of reaching efficient and early go/no go decisions.Be part of this European meeting featuring first class plenary sessions and interactive workshops and experience excellent networking opportunities in stimulating surroundings.View programmeRegister online

Please forward this invitation to interested colleagues also.Looking forward to seeing you!Sincerely yoursConference ChairDr. Yves DonazzoloPresident CLUB PHASE IIntercom Kongresse GmbHAntje BlmekeEppendorfer Baum 39a20249 Hamburg (Germany)Phone: +49 40 480610 61Telefax: +49 40 480610 66E-Mail: abloemeke@intercom.deWeb: www.intercom..de

Disclaimer 2013 Intercom Kongresse GmbHEppendorfer Baum 39a, 20249 Hamburg/GermanyUSt-ID DE 1615 400 24, Registry court Hamburg, HRB 113503. All rights reserved. Responsible for contents pursuant to 6 MDStV Managing Director Alexandra Werner.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more